

PATENT SPECIFICATION

(11) 1 381 588

1 381 588

- (21) Application No. 43187/73 (22) Filed 14 Sept. 1973
 (31) Convention Application No. 2 246 013 (32) Filed 20 Sept. 1972 in (19)
 (33) Germany (DT)
 (44) Complete Specification published 22 Jan. 1975
 (51) INT CL³ A61J 3/10
 (52) Index at acceptance A5B 750 75Y 764



(54) PROCESS FOR THE PREPARATION OF POROUS TABLETS

- (71) We, BOEHRINGER MANN-HEIM G.M.B.H., of Mannheim-Waldhof, Federal Republic of Germany, a Body Corporate organised under the laws of the Federal Republic of Germany, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—
- The present invention is concerned with a new process for the preparation of porous tablets.
- Because of the ease of handling and the simplicity of dosing, not only pharmaceutical tablets but also reagent tablets are used to an ever increasing extent for diagnostic and analytical purposes. Most active materials and reagents cannot be tableted by themselves since they are damaged by solvents and organic solvent, in which at least one of the components partially dissolves, to give a stiff slurry which is formed in special machines to give tablets, whereafter the tablets are carefully dried. Upon evaporation of the solvent, the substances dissolved therein stick together the undissolved particles, whereby the tablets receive their strength; at the same time, small hollow spaces remain behind into which the solvents can again penetrate upon dissolving again. Although these tablets are satisfactory from the point of value of speed of dissolving, they are frequently too soft and brittle due to the presence of the very fine canals so that difficulties arise with packing and transport. Furthermore, the use of the process is limited due to the fact that many reagents, especially enzymes and
- readily break cases, tend to be obtained by agents, such as the like, phosphates as talc, si
- Whereas it logically ceuticals, speaking, etc. cannot be produced or can only be produced with difficulty in this manner. In particular, the lubricants which are generally used and which are intended to prevent the adherence of the tablet masses in the presses used are mostly insoluble in water. It has, therefore, been suggested to press together adhesive reagents with very large amounts of readily tabletable fillers or to use very high pressures for the pressing. However, both processes are unsatisfactory since the tablets formed are either unnecessary large or are too hard and difficult to break down.
- Another known process gives so-called "moulded tablets". In this case, the tablet components are pasted with water or an
- organic solvent, in which at least one of the components partially dissolves, to give a stiff slurry which is formed in special machines to give tablets, whereafter the tablets are carefully dried. Upon evaporation of the solvent, the substances dissolved therein stick together the undissolved particles, whereby the tablets receive their strength; at the same time, small hollow spaces remain behind into which the solvents can again penetrate upon dissolving again. Although these tablets are satisfactory from the point of value of speed of dissolving, they are frequently too soft and brittle due to the presence of the very fine canals so that difficulties arise with packing and transport. Furthermore, the use of the process is limited due to the fact that many reagents, especially enzymes and
- ERRATA
- SPECIFICATION No. 1,381,588
- Page 3, line 57, for nitotinamide read nicotinamide
- Page 4, Table 3, right hand column, bottom line, for 15 read <15
- Page 4, line 7, for 116 mg. read 11.6 mg.
- THE PATENT OFFICE
 24th March, 1975
- The tablet components are to be understood to mean all those components, other than the sublimable adjuvant, which constitute the tablet, such as active materials and pharmaceutical carriers and diluents.
- Due to the hard pressing in conventional tableting machines, there are formed tablets of great mechanical stability and, at the same time, the addition of sparingly soluble lubricants is unnecessary. Since the pressed

SEE ERRATA SLIP ATTACHED

PATENT SPECIFICATION

(11) 1 381 588

1 381 588

- (21) Application No. 43187/73 (22) Filed 14 Sept. 1973
 (31) Convention Application No. 2 246 013 (32) Filed 20 Sept. 1972 in (19)
 (33) Germany (DT)
 (44) Complete Specification published 22 Jan. 1975
 (51) INT CL² A61J 3/10
 (52) Index at acceptance A5B 750 75Y 764



(54) PROCESS FOR THE PREPARATION OF POROUS TABLETS

(71) We, BOEHRINGER MANN-HEIM G.M.B.H., of Mannheim-Waldhof, Federal Republic of Germany, a Body Corporate organised under the laws of the Federal Republic of Germany, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The present invention is concerned with a new process for the preparation of porous tablets.

Because of the ease of handling and the simplicity of dosing, not only pharmaceutical tablets but also reagent tablets are used to an ever increasing extent for diagnostic and analytical purposes. Most active materials and reagents cannot be tabletted by themselves since they form hard tablets which do not readily break down and, in addition, in many cases, tend to stick in the presses used.

Tablets which break down quickly are only obtained by the addition of disintegration agents, such as carboxymethyl-cellulose, starch or the like, filling materials, such as lactose, phosphates and the like, and lubricants, such as talc, stearic acid, paraffin or the like. Whereas it is simple to find suitable physiologically compatible adjuvants for pharmaceuticals, reagent tablets which, generally speaking, are to give optically clear solutions, cannot be produced or can only be produced with difficulty in this manner. In particular, the lubricants which are generally used and which are intended to prevent the adherence of the tablet masses in the presses used are mostly insoluble in water. It has, therefore, been suggested to press together adhesive reagents with very large amounts of readily tablettable fillers or to use very high pressures for the pressing. However, both processes are unsatisfactory since the tablets formed are either unnecessary large or are too hard and difficult to break down.

Another known process gives so-called "moulded tablets". In this case, the tablet components are pasted with water or an

organic solvent, in which at least one of the components partially dissolves, to give a stiff slurry which is formed in special machines to give tablets, whereafter the tablets are carefully dried. Upon evaporation of the solvent, the substances dissolved therein stick together the undissolved particles, whereby the tablets receive their strength; at the same time, small hollow spaces remain behind into which the solvents can again penetrate upon dissolving again. Although these tablets are satisfactory from the point of value of speed of dissolving, they are frequently too soft and brittle due to the presence of the very fine canals so that difficulties arise with packing and transport. Furthermore, the use of the process is limited due to the fact that many reagents, especially enzymes and indicators, are damaged by solvents and organic solvent vapours make necessary special safety requirements in the production of the tablets.

It is, therefore, an object of the present invention to provide a process which permits the production of readily dissolved, porous tablets in conventional tablet presses, without having to add lubricants, explosive agents or solvents.

Thus, according to the present invention, there is provided a process for the production of porous tablets, wherein the tablet components as hereinafter defined are hard pressed together with at least one inert solid adjuvant, which sublimates at a temperature which does not adversely affect any of the tablet components, whereafter said adjuvant is sublimated.

The tablet components are to be understood to mean all those components, other than the sublimable adjuvant, which constitute the tablet, such as active materials and pharmaceutical carriers and diluents.

Due to the hard pressing in conventional tableting machines, there are formed tablets of great mechanical stability and, at the same time, the addition of sparingly soluble lubricants is unnecessary. Since the pressed

SEE ERRATA SLIP ATTACHED

tablets, in contradistinction to the "moulded tablets", are form-stable, they no longer shrink upon removal of the adjuvant. Therefore, when the adjuvant is removed, it leaves behind comparatively large hollow spaces and canals, through which solvent can penetrate.

As adjuvants, there can be used, in principle, all readily sublimable materials or materials which can readily be converted into gaseous decomposition products and which are readily tabletable and do not react with the other components of the tablets. By way of example, there may be mentioned urethane, urea, ammonium carbonate and bicarbonate, hexamethylene-tetramine, benzoic acid, phthalic anhydride, naphthalene and camphor, urethane being specially preferred.

The tablet masses for water-soluble reagent tablets and pharmaceutical tablets can, in addition to one or more active materials, contain conventional water soluble carrier materials, for example sodium chloride, potassium chloride, borax, phosphates, oligosaccharides, polyethylene glycols, tensides and other appropriate inorganic and organic materials. The volatile solid adjuvants can account for 5—50% by weight and preferably 10—30% of the total tablet mass, it being understood that in the case of a high proportion of adjuvant, there are formed comparatively large hollow spaces and thus tablets which break down more quickly but are also more brittle than in the case of using a small proportion of adjuvant. Although the adjuvants can be completely removed, the production time for the new tablets according to the present invention is shortened when the adjuvants are allowed to remain behind in the tablets in trace amounts, for example of less than 1% by weight.

In the case of sufficient thermal stability, the adjuvants can be removed by simple heating of the tablets above the sublimation or decomposition point. In the case of sensitive tablet components, for example of enzymes, it is advantageous to work in a vacuum, the conventional freeze drying plants with con-

densation separator having proved to be especially advantageous for this purpose.

The following Examples are given for the purpose of illustrating the present invention:—

Example 1.

Tablet A: 1.850 kg. potassium chloride are sieved and pressed to form tablets of 8 mm. diameter containing 185 mg. potassium chloride.

Tablet B1: 1.850 kg. potassium chloride are mixed with 350 g. urethane (ethyl-urethane), sieved and pressed to form tablets of 8 mm. diameter containing 185 mg. potassium chloride and 35 mg. urethane.

The urethane is subsequently sublimated off from these tablets for 5 hours in a freeze drying plant at 20°C. and at a pressure of 10^{-1} to 10^{-3} mm.Hg.

Tablet B2: 1.850 kg. potassium chloride are mixed with 350 g. ammonium bicarbonate, sieved and pressed to form tablets of 8 mm. diameter containing 185 mg. potassium chloride and 35 mg. ammonium bicarbonate.

The ammonium bicarbonate is driven off from these tablets for 8 hours in a drying cabinet at 90°C.

Tablet B3: 1.850 kg. potassium chloride are mixed with 350 g. urea, sieved and pressed to form tablets of 8 mm. diameter containing 185 mg. potassium chloride and 35 mg. urea.

The urea is sublimated off from these tablets for 16 hours in a vacuum cabinet at 110°C. and 15 mm.Hg.

Tablet B4: 1.850 kg. potassium chloride are mixed with 350 g. urotropin, sieved and pressed to form tablets of 8 mm. diameter containing 185 mg. potassium chloride and 35 mg. urotropin.

The urotropin is removed from these tablets for 16 hours in a vacuum cabinet at 90°C. and 15 mm.Hg.

The results of tests carried out on these tablets are set out in the following Table 1:—

TABLE 1

tablet	height (mm.)	hardness (kg.)	dissolving time (sec.)	breakability (sec.)
A	2.3	9.5	240	150
B1 — B4	2.9	3.5	105	30

Determination of the tablet hardness: with a Erweka hardness tester.

Determination of the dissolving time: 200 ml. water at ambient temperature are stirred at a rate of 150 r.p.m. in a 250 ml. glass

beaker with a curved glass rod. The time needed for complete dissolving is determined.

Determination of breakability: a tablet placed on its edge in a Petri dish is compressed

with a rod with an applied weight of 500 g. The Petri dish is filled with water at ambient temperature and the time determined for the tablet to break.

Example 2.

5 Tablet A: 1.5 kg. dextrose are granulated with 40% alcohol, dried and sieved. The granulate is dry mixed with 50 g. polyethylene glycol (M.W. 5000—6000) and
10 pressed to form tablets of 8 mm. diameter containing 150 mg. dextrose.

15 Tablet B1: 1.550 kg. dextrose-polyethylene glycol granulate are dry mixed with 300 g. urethane. The tablet mass is pressed to form tablets of 8 mm. diameter containing 150 mg. dextrose and 30 mg. urethane.

20 The urethane is sublimated from these tablets for 8 hours in a drying cabinet at 40°C.

Tablet B2: 1.550 kg. dextrose-polyethylene glycol granulate are dry mixed with 300 g. ammonium carbonate. The tablet mass is pressed to form tablets of 8 mm.

diameter containing 150 mg. dextrose and 30 mg. ammonium carbonate. 25

The ammonium carbonate is removed from these tablets for 8 hours in a drying cabinet at 75°C.

30 Tablet B3: 1.550 kg. dextrose-polyethylene glycol granulate are dry mixed with 300 g. benzoic acid. The tablet mass is pressed to form tablets of 8 mm. diameter containing 150 mg. dextrose and 30 mg. benzoic acid. 35

The benzoic acid is sublimated from these tablets for 16 hours in a vacuum cabinet at 90°C. and 15 mm.Hg.

40 Tablet B4: 1.550 kg. dextrose-polyethylene glycol granulate are dry mixed with 300 g. camphor. The tablet mass is pressed to form tablets of 8 mm. diameter containing 150 mg. dextrose and 300 mg. camphor.

45 The camphor is removed from these tablets for 8 hours in a freeze drying device at 40°C. and 10^{-1} to 10^{-3} mm.Hg.

50 The results of tests carried out on these tablets, in the manner described in Example 1, are set out in the following Table 2:—

TABLE 2

tablet	height (mm.)	hardness (kg.)	dissolving time (sec.)	breakability (sec.)
A	2.7	4.5	360	210
B1 - B4	3.3	1.0	270	<10

Example 3.

55 Tablet A: 15 g. polyethylene glycol (M.W. 5000—6000) are dissolved in 40% alcohol. With this solution, there are granulated 388 g. glucose and 12.5 g. nitotinamide - adenine - dinucleotide (NAD), 3.75 g. 2,5 - diphenyl - 3 - (4,5-dimethyl - thiazolyl - 2) - tetrazolium bromide (MTT) and 0.75 g. phenazine methosulphate (PMS) are added there-
60 to. The mixture is pressed to form tablets of 12 mm. diameter, each tablet containing 12.5 mg. NAD, 3.75 mg. MTT and 0.75 mg. PMS.

65 Tablet B: 15 g. polyethylene glycol (M.W. 5000—6000) are dissolved in 40%

alcohol. With this solution, there are granulated 388 g. glucose, which is then dried and sieved. The granulate obtained is dry mixed with 12.5 g. NAD, 3.75 g. MTT, 0.75 g. PMS and 80 g. urethane. The mixture is pressed to form reagent tablets of 12 mm. diameter which contain, per tablet, 12.5 mg. NAD, 3.75 mg. MTT and 0.75 mg. PMS. The urethane is sublimated from these tablets for 8 hours in a freeze drying plant at 0°C. and 10^{-1} or 10^{-3} mm.Hg. 70 75

80 The results of tests carried out on these tablets, in the manner described in Example 1, are set out in the following Table 3:—

TABLE 3

tablet	height (mm.)	hardness (kg.)	dissolving time (sec.)	breakability (sec.)
A	3.5	12	660	<40
B	4.2	3	480	15

Example 4.

- 5 Tablet A: 500g. sodium chloride are ground, mixed with 116 g. sodium *p*-nitrophenyl phosphate, precompressed and sieved. There are pressed tablets of 5 mm. diameter containing 116 mg. sodium *p*-nitrophenyl phosphate.
- 10 Tablet B: 500 g. sodium chloride are ground, mixed with 116 g. sodium *p*-nitrophenyl phosphate and 134 g. urethane, precom-

pressed and sieved. There are pressed tablets of 5 mm diameter containing 11.6 mg. sodium *p*-nitrophenyl phosphate. These tablets are heated for 10 hours in a drying cabinet at 30°C. to sublimate the urethane.

The results of tests carried out on these tablets, in the manner described in Example 1, are set out in the following Table 4: 20

TABLE 4

tablet	height (mm.)	hardness (kg.)	dissolving time (sec.)	breakability (sec.)
A	1.9	3	300	60
B	2.4	1	120	<10

WHAT WE CLAIM IS:—

- 25 1. A process for the production of porous tablets, wherein the tablet components are hard pressed together with at least one inert solid adjuvant which sublimes at a temperature which does not adversely affect any of the tablet components, whereafter said adjuvant is sublimated.
- 30 2. A process according to claim 1, wherein the adjuvant is sublimated in a vacuum.
- 35 3. A process according to claim 1 or 2, wherein the adjuvant used is urethane, urea, ammonium carbonate, ammonium bicarbonate, hexamethylene-tetramine, benzoic acid, phthalic anhydride, naphthalene or camphor.
- 40 4. A process according to any of the preceding claims, wherein the amount of adjuvant used is 5—50% by weight, referred to the total tablet mass.

5. A process according to claim 4, wherein the amount of adjuvant used is 10 to 30% by weight, referred to the total tablet mass.

6. A process according to any of the preceding claims, wherein the tablets additionally contain conventional water-soluble carrier materials. 45

7. Process according to claim 1 for the production of porous tablets, substantially as hereinbefore described and exemplified. 50

8. Porous tablets, whenever produced by the process according to any of claims 1 to 7.

VENNER, SHIPLEY & CO.,
Chartered Patent Agents,
Rugby Chambers,
2, Rugby Street,
London WC1N 3QU.
Agents for the Applicants.